FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending March 26, 2008
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
Following a re-valuation of the cash element of the notional investment held
within the US Retirement Savings Plan ("The Plan"), which is notionally held in
GSK Ordinary share ADRs, the Administrators of the Plan notified GlaxoSmithKline
plc and the under-mentioned person on 26 March 2008 of an increase in the
notional allocation of Ordinary share ADRs on 24 March 2008 at a price of $42.14
per ADR:-
Dr R G Greig 6
This notification relates to a transaction notified in accordance with
Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
26 March 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: March 26, 2008 By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc